Vantis Vascular, Inc. appears in FDA records as the applicant for CrossFAST percutaneous catheter clearances, both reviewed by the Cardiovascular advisory committee under regulation 21 CFR 870.1250 and product code DQY. The company describes itself as a developer of medical devices for vascular interventionalists treating complex cases. The documented record covers two 510(k) clearances and one peer-reviewed early clinical experience article, each tied to a specific product configuration rather than a broad commercial catalog. [1][2][3][8]

The CrossFAST guide extension clearance

FDA record K242276, dated September 30, 2024, names Vantis Vascular, Inc. as applicant for the CrossFAST Integrated Microcatheter Guide Extension System, a Class II percutaneous catheter under 21 CFR 870.1250 and product code DQY. The indications for use state the system is intended for use with guide catheters to access discrete regions of the coronary and peripheral vasculature and to assist placement of interventional devices. The clearance letter was addressed to Angela Thompson, listed as Vice President, Quality, at the San Jose, California address on the filing. [8]

The 2026 advanced delivery clearance

A second clearance, K262817, was received August 7, 2026 and decided September 18, 2026 as substantially equivalent (SESE) with a Special clearance type and a summary statement. The device is the CrossFAST Integrated Microcatheter Advanced Delivery System, again a Class II percutaneous catheter under 21 CFR 870.1250 and product code DQY, reviewed by the Cardiovascular panel. The FDA database entry and the clearance letter both list Vantis Vascular, Inc. at 2570 N First St., Suite 200, San Jose, California, with Mai-Ly Wilcox identified as VP of Regulatory and Quality Affairs. [1][2][5]

An independent FDA record index lists the same K262817 details and quotes an intended-use statement for CrossFAST (CFM60) covering access to discrete regions of the coronary and peripheral vasculature with guide catheters and placement of interventional devices. That index also reports the test results supported substantial equivalence to the predicate device for the same intended use. [9]

Documented device components

The manufacturer’s published sell sheet describes CrossFAST as a dual monorail microcatheter advanced delivery system for complex coronary and peripheral interventions, built from an inner microcatheter and an outer delivery catheter. It lists an outer diameter of 0.014 inches, a recommended guide catheter of at least 6F with 0.070 inch (1.78 mm) inner diameter, a 31 cm hydrophilic coating and a 150 cm working length. The same document attributes the coupling of inner and outer components to patented DuoPRO interlocking technology, allowing advancement as one unit. [4]

The company website states that Vantis Vascular develops medical devices to help vascular interventionalists treat complex cases, with an emphasis on coronary interventions. A footnote on that site cites a November 2021 preclinical study by Fischell, Payne and colleagues on a next-generation guide extension system, and the page carries a San Jose, California address matching the FDA filings. [3]

Published early clinical experience

The Journal of the Society for Cardiovascular Angiography & Interventions published an original research article in its March 2026 issue, Volume 5, Issue 3, titled “Early Clinical Experience With CrossFAST, a Novel, Microcatheter-Led Delivery System for Complex Percutaneous Coronary Intervention.” The article is open access, appears in a coronary special issue edited by Alexandra Lansky, and lists NIH SBIR Grant # 1R43HL1512835-01A1 as partial funding. Its disclosures note advisory board roles for Boston Scientific and Medtronic for one author and nothing to disclose for Michael Yang. [7]